| ICH Guideline Videos by year |
| ICH | Programs | Speakers | Video | Materials | |
|---|---|---|---|---|---|
| KOR | ENG | Files | |||
| ICH | |||||
| ICH | ICH Cooperation activity and implementation status of ICH guidelines in Korea | Heesung Kim (NIFDS, MFDS) |
|||
| Quality | |||||
| Q3C(R9) | Risk-Based Approach for Evaluation and Control Strategy of Residual Solvents in Pharmaceuticals | Ji Sun Yoo (Daewoong Pharm) |
|||
| Q3D(R2) | Elemental Impurity Risk Assessment | Andrew Teasdale (ATCMC Solutions Limited) |
|||
| Q9(R1) | Integration of QRM in Quality Management Systems -Quality Management System Applications of Risk-Based Decision-Making Approaches | Marion de la Cruz-Kuo (MSD) |
|||
| Q2(R2)/Q14 | Analytical Procedure Development and Change Management Concepts in ICH Q14 | Nina Cauchon (Amgen) |
|||
| Q2(R2)/Q14 | ICH Q2(R2)/Q14 Training based on Training Materials | Yukio Hiyama (National Institute of Health Sciences) |
|||
| Q3E EWG | ICH Q3E: Guideline for Extractable and Leachables | Patricia Parris (Pfizer) |
|||
| Multidisciplinary | |||||
| M7(R2) | M7(R2): N-Nitrosamines -Past, Present and Future | Andrew Teasdale (ATCMC Solutions Limited) |
|||
| M7(R2) | ICH M7(R2) - Risk-Based Assessment and Control Strategies for Genotoxic Impurities Using Real-World Case Studies (Including Manufacturing Processes) | Kazusei Komatsu (Shionogi) |
|||
| M4Q(R2) EWG | ICH M4Q(R2) and the Way Forward | Lawrence Yu (FDA) |
|||
| M14 EWG | Introduction to the ICH M14 Guideline (Step 3) | Bongkyoo Choi (GC Biopharma) |
|||
| M15 EWG | Envisioning Global Harmonization of MIDD: Opportunities and Challenges in the Implementation of the New ICH M15 MIDD Guidelines | Jiawei Wei (Novartis) Daisuke Iwata (PMDA) |
|||
| Efficacy | |||||
| E2C(R2) | Mastering PBRER Preparation: Best Practices and Global Regulatory Insights | Minkyung Shin (Selta Square) |
|||
| E6(R3) | ICH E6(R3) – The implementation | Rebecca Stanbrook (Novartis Pharma AG) |
|||
| E14/S7B | Best practice condideration for the in vitro cardiac ion channel and in vivo QT studies (S7B Q&A, Best practice) | Joung-Wook Seo (Korea Institute of Toxicololgy) |
|||
| Safety | |||||
| S2(R1) | Interpretation of S2(R1) Genotoxicity Data, Decision Criteria, and Regulatory Response Cases | Hyun-Kul Lee (Corestemchemon) |
|||
| S10 | Photosafety Evaluation of Pharmaceuticals since Implementation of ICH S10 | Daniel Bauer (Novartis Pharma AG) |
|||
